1. Li TC, Chan MC, Lee N. Clinical implication of antiviral resistance in influenza. Viruses 2015; 7(9): 4929-44.
2. Treanor JJ. Influenza Viruses. In: RA Kaslow, LR Stanberry, JW Le Duc. editors. Viral Infections of Humans- epidemiology and control. New York: Springer Science + Business Media; 2014; 455-78.
3. Saito R, Li D, Shimomura C, Masaki H, Le MQ, Nguyen HL, et al. An off-seasonal amantadine-resistant H3N2 influenza outbreak in Japan. Tohoku Journal of Experimental Medicine 2006; 210(1): 21-7.
4. Król E, Rychłowska M, Szewczyk B. Antivirals-current trends in fighting influenza. Acta biochimica Polonica 2014; 61(3): 495-504.
5. Pielak RM, Chou JJ. Influenza M2 proton channels. Biochimica et Biophysica Acta 2011; 1808(2): 522-9.
6. Abed Y, Goyette N, Boivin G. Generation and characterization of recombinant influenza A(H1N1) viruses harboring amantadine resistance mutations. Antimicrobial Agents and Chemotherapy 2005; 49(2): 556-9.
7. Nelson MI, Simonsen L, Viboud C, Miller MA, Holmes EC. The origin and global emergence of adamantine resistant A (H3N2) influenza viruses. Virology 2009; 388(2): 270-8.
8. Hayden FG, de Jong MD. Emerging influenza antiviral resistance threats. Journal of Infectious Diseases 2011; 203(1): 6-10.
9. Deyde VM, Xu X, Bright RA, Shaw M, Smith CB, Zang Y, et al. Surveillance of resistance to adamantanes among influenza A (H3N2) and A (H1N1) viruses isolated worldwide. Journal of Infectious Diseases 2007; 196(2): 249-57.
10. Bright RA, Medina MJ, Xu X, Perez-Oronoz G, Wallis TR, Davis XM, et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005; 366 (9492): 1175-81.
11. Dong G, Peng C, Luo J, Wang C, Han L, Wu B, et al. Adamantane-resistant influenza A viruses in the world (1902-2013): frequency and distribution of M2 gene mutations. PLoS One 2015; 10(3): e0119115.
12. Hurt AC. The epidemiology and spread of drug resistant human influenza viruses. Current Opinion in Virology 2014; 8: 22-9.
13. Yavarian J, Azad TM, Zheng X, Gregory V, Lin YP, Hay A. Amantadine resistance in relation to the evolution of influenza A (H3N2) viruses in Iran. Antiviral Research 2010; 88(2): 193-6.
14. Yavarian J, Mokhtari Azad T, Shafiei Jandaghi NZ, Nategh R. Amantadine-resistant influenza A (H3N2) viruses in Iran. Acta Virologica 2009; 53(2): 135-8.
15. Yavarian J, Shafiei Jandaghi NZ, Naseri M, Mokhtari Azad T. Characterization of variations in PB2, NS1, M, neuraminidase and hemagglutinin of influenza A (H3N2) viruses in Iran. Jundishapur Journal of Microbiology 2014; 7(3): e9089.
16. World Health Organization. CDC protocol of realtime RTPCR for influenza A (H1N1). 2009. Available from http://www.who.int/csr/resources/publications/swineflu/CDCRealtimeRTPCR_SwineH1Assay-2009_20090430.pdf.
17. Schnell JR, Chou JJ. Structure and mechanism of the M2 proton channel of influenza A virus. Nature 2008; 451: 591-6.
18. Byarugaba DK, Ducatez MF, Erima B, Mworozi EA, Millard M, Kibuuka H, et al. Molecular epidemiology of influenza A/H3N2 viruses circulating in Uganda. PloS one 2011; 6(11): e27803.
19. Furuse Y, Suzuki A, Kamigaki T, Oshitani H. Evolution of the M gene of the influenza A virus in different host species: large-scale sequence analysis. Virology Journal 2009; 6: 67.
20. Melidou A, Kyriazopoulou V, Diza E, Alexiou S, Pierroutsakos Y. Antiviral resistance of influenza A (H3N2) strains isolated in northern Greece between 2004 and 2007. Euro Surveillance 2009; 14(4). 19104.
)